Physician profile
Anna Liang
NPI 1982241261
$12,148.72
in general payments reported to CMS, 2019-2025
29 companies · $2,631 in 2025
The $2,631 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,795 · 2022: $2,515 · 2023: $1,677 · 2024: $1,530 · 2025: $2,631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,531 · Education: $307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,531.24 |
| Education | $307.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,040.27 | 2021-2025 | |
| Janssen Biotech, INC. | $944.20 | 2021-2025 | Tremfya |
| Lilly USA, LLC | $940.85 | 2021-2025 | Olumiant, Taltz, Ebglyss |
| Ucb, INC. | $761.11 | 2021-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $729.77 | 2021-2025 | |
| Galderma Laboratories, L.P. | $689.48 | 2021-2025 | Nemluvio, Aklief |
| Sun Pharmaceutical Industries INC. | $683.34 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| Regeneron Healthcare Solutions, INC. | $545.31 | 2021-2025 | Dupixent, Libtayo |
| Arcutis Biotherapeutics, INC. | $490.37 | 2024-2025 | Zoryve |
| Pfizer INC. | $456.23 | 2021-2025 | |
| Genzyme Corporation | $411.04 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $397.32 | 2022-2024 | |
| Amgen INC. | $369.17 | 2021-2023 | Otezla, Enbrel |
| Leo Pharma INC. | $329.89 | 2021-2025 | Adbry |
| Allergan, INC. | $320.71 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $271.16 | 2021-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Incyte Corporation | $187.06 | 2021-2025 | Opzelura |
| Organon LLC | $175.99 | 2025 | Vtama |
| Dermira, INC. | $61.64 | 2021 | |
| Vyne Pharmaceuticals INC. | $59.35 | 2021 | |
| Journey Medical Corporation | $53.53 | 2021-2022 | |
| Almirall LLC | $44.13 | 2021-2022 | |
| Helsinn Therapeutics (U.S.), INC. | $42.03 | 2021-2025 | Valchlor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.96 | 2022-2025 | Spevigo |
| Mayne Pharma Commercial LLC | $32.69 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $26.25 | 2021 | |
| Integra Lifesciences Corporation | $18.23 | 2024 | Integra, Integra Dermal Regeneration Template, Surgimend |
| Verrica Pharmaceuticals INC. | $16.71 | 2023 | Ycanth |
| Biodermis LLC | $11.93 | 2025 | Pro-Sil, Biocorneum, Epi-Derm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Liang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.